SUBSCRIBE
SUBSCRIBE

Anavex Life Sciences Corp.

NEWS
TRICON: Clinical Exome Sequencing More Efficient and Unbiased, Says Pathologist
Drug Development
TRICON: Alzheimer’s Drug Saw 80% Reversal in Memory Loss, Say Anavex CEO
February 18, 2015
 · 
2 min read
Load More
JOBS
IN THE PRESS
Press Releases
Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024
December 2, 2024
 · 
3 min read
Press Releases
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA
November 26, 2024
 · 
5 min read
Press Releases
Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal
November 25, 2024
 · 
4 min read
Press Releases
Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
October 31, 2024
 · 
7 min read
Press Releases
Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
October 17, 2024
 · 
9 min read
Press Releases
Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024
September 3, 2024
 · 
3 min read
Press Releases
Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
August 7, 2024
 · 
11 min read
Press Releases
Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024
August 1, 2024
 · 
3 min read
Press Releases
Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference
July 30, 2024
 · 
8 min read
Press Releases
Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer’s Association Conference
July 29, 2024
 · 
8 min read
Load More